Last reviewed · How we verify
Pegfilgrastim-Cbqv
Pegfilgrastim-Cbqv is a Granulocyte colony-stimulating factor (G-CSF) analog Small molecule drug developed by Coherus Oncology, Inc.. It is currently FDA-approved for Chemotherapy-induced neutropenia (CIN) in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy, Reduction of duration of severe neutropenia in patients with non-myeloid malignancies receiving myeloablative chemotherapy followed by hematopoietic stem cell transplantation. Also known as: Neulasta, pegfilgrastim biosimilar.
Pegfilgrastim-Cbqv is a pegylated granulocyte colony-stimulating factor (G-CSF) analog that stimulates the proliferation and differentiation of neutrophil progenitor cells to increase circulating neutrophil counts.
Pegfilgrastim-Cbqv is a pegylated granulocyte colony-stimulating factor (G-CSF) analog that stimulates the proliferation and differentiation of neutrophil progenitor cells to increase circulating neutrophil counts. Used for Chemotherapy-induced neutropenia (CIN) in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy, Reduction of duration of severe neutropenia in patients with non-myeloid malignancies receiving myeloablative chemotherapy followed by hematopoietic stem cell transplantation.
At a glance
| Generic name | Pegfilgrastim-Cbqv |
|---|---|
| Also known as | Neulasta, pegfilgrastim biosimilar |
| Sponsor | Coherus Oncology, Inc. |
| Drug class | Granulocyte colony-stimulating factor (G-CSF) analog |
| Target | G-CSF receptor (GCSFR) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
This drug binds to G-CSF receptors on hematopoietic progenitor cells in the bone marrow, promoting their maturation and release into the bloodstream. The pegylation extends the drug's half-life, allowing for less frequent dosing compared to non-pegylated G-CSF. It is used to prevent chemotherapy-induced neutropenia and reduce the risk of febrile neutropenia in cancer patients receiving myelosuppressive chemotherapy.
Approved indications
- Chemotherapy-induced neutropenia (CIN) in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy
- Reduction of duration of severe neutropenia in patients with non-myeloid malignancies receiving myeloablative chemotherapy followed by hematopoietic stem cell transplantation
Common side effects
- Bone pain
- Fatigue
- Headache
- Nausea
- Injection site reactions
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer (PHASE2, PHASE3)
- Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma (PHASE2)
- Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia (PHASE2)
- A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT (PHASE2)
- Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (PHASE2)
- Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia (PHASE2)
- Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pegfilgrastim-Cbqv CI brief — competitive landscape report
- Pegfilgrastim-Cbqv updates RSS · CI watch RSS
- Coherus Oncology, Inc. portfolio CI
Frequently asked questions about Pegfilgrastim-Cbqv
What is Pegfilgrastim-Cbqv?
How does Pegfilgrastim-Cbqv work?
What is Pegfilgrastim-Cbqv used for?
Who makes Pegfilgrastim-Cbqv?
Is Pegfilgrastim-Cbqv also known as anything else?
What drug class is Pegfilgrastim-Cbqv in?
What development phase is Pegfilgrastim-Cbqv in?
What are the side effects of Pegfilgrastim-Cbqv?
What does Pegfilgrastim-Cbqv target?
Related
- Drug class: All Granulocyte colony-stimulating factor (G-CSF) analog drugs
- Target: All drugs targeting G-CSF receptor (GCSFR)
- Manufacturer: Coherus Oncology, Inc. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Chemotherapy-induced neutropenia (CIN) in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy
- Indication: Drugs for Reduction of duration of severe neutropenia in patients with non-myeloid malignancies receiving myeloablative chemotherapy followed by hematopoietic stem cell transplantation
- Also known as: Neulasta, pegfilgrastim biosimilar
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing